Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
PH Research, S.L.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who are 18 years or older;
Patients with histological or, if not possible, cytologic confirmed adenocarcinoma of the pancreas.
Patients with metastatic pancreatic cancer;
Patient with an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 2
Adequate hematopoietic, hepatic and renal function:
Neutrophil count \>= 1.5 x 10\*9/L;
Platelet count \>= 100 x 10\*9/L;
Bilirubin \<= 1.5 x ULN;
AST and/or ALT \<= 2.5 x ULN;
Serum creatinine \<= 1.5 x ULN.
Investigators must ensure that patients enrolled in the study will be available for all study procedures, including tumor biopsy, chemotherapy treatment, and follow up.
Investigators must ensure that patients have the ability to understand the requirements of the study and provide signed informed consent.
Women of childbearing potential and men who wish to participate in the study must agree to use adequate contraception since the signing of informed consent until at least 3 months after stopping the study medication;
Signed Informed Consent.
You may not be if
Active or uncontrolled infections or serious illnesses or medical conditions that could interfere with patient eligibility for treatment;
History of any psychiatric condition that might impair patient?s ability to understand or to comply with the requirements of the study or to provide informed consent;
Concurrent anticancer therapy;
Pregnant or breast-feeding women (documented methods of birth control are required in those with reproductive potential);
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs;
History of life threatening reaction to gemcitabine or abraxane;
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) \<=1.
Previous treatment with chemotherapy or chemoradiotherapy for advanced pancreatic cancer.
Clareo Health | Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer
